Seeking Alpha

Aegerion Pharmaceuticals (AEGR)

  • Nov. 6, 2014, 8:31 AM
    • Aegerion Pharmaceuticals (NASDAQ:AEGR) acquires Myalept (metreleptin for injection) from AstraZeneca (NYSE:AZN) for $325M. The drug is indicated for the treatment of leptin deficiency in patients with generalized lipodystrophy. It is the first and only product approved in the U.S. to treat the disease.
    • Myalept has Orphan Drug status in the U.S., European Union and Japan.
    | Comment!
Visit Seeking Alpha's
AEGR vs. ETF Alternatives
Company Description
Aegerion Pharmaceuticals Inc is a biopharmaceutical company. The Company currently operates in one business segment focusing on the development and commercialization of its product, lomitapide.
Sector: Healthcare
Industry: Biotechnology
Country: United States